CD274 and non-small cell lung carcinoma: The European Medicines Agency approved adjuvant durvalumab following CRT in stage III NSCLC for patients with PD-L1 TPS ≥ 1% [10], while the Food and Drug Administration (FDA) and Health Canada granted approval regardless of PD-L1 expression [11,12].